Copyright © 2025 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{162812,
        author = {Chakshu Walia and Deepali Thakur and Parul Verma},
        title = {Review on Sodium Valproate: Mechanism, Pharmacokinetics, Adverse Effects},
        journal = {International Journal of Innovative Research in Technology},
        year = {},
        volume = {10},
        number = {11},
        pages = {81-88},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=162812},
        abstract = {Valproate (valproic acid, VPA, sodium valproate, and valproate semi sodium forms) are medications primarily used to treat epilepsy and bipolar disorder and prevent migraine headaches. They are useful for the prevention of seizures in those with absence seizures, partial seizures, and generalized seizures. They can be given intravenously or by mouth, and the tablet forms exist in both long- and short-acting formulations.  Valproate's precise mechanism of action is unclear. Proposed mechanisms include affecting GABA levels, blocking voltage-gated sodium channels, inhibiting histone deacetylases, and increasing LEF1. Valproic acid is a branched short-chain fatty acid (SCFA), a derivative of valeric acid. },
        keywords = {fetal, valproate, Pharmacokinetics, toxicity},
        month = {},
        }